The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
HOME > ORGANIZATION
ORGANIZATION
- JPWA Calls on MHLW to Narrow Down Range of Pharmacies Subjected to Medical Fee Cut Rule for Low Price Settlement Rates
March 20, 2015
- Kyokai Kenpo Aims to Increase Generic Usage Rate to 65.1%
March 20, 2015
- JHSF Calls for Tax Incentives to Promote Investment in Regenerative Medicine
March 19, 2015
- Majority of Doctors Dissatisfied with Existing Treatments for AD, Pancreatic Cancer: JHSF
March 18, 2015
- Bone-Forming Agents Most Needed for Osteoporosis in 2025: JHSF Survey
March 18, 2015
- JSGM President Calls for Generic Share Target of 80% by FY2020
March 12, 2015
- Medwatcher Accuses HPV Vaccine Makers of Violating JPMA’s Promotion Code
March 2, 2015
- JPMA to Inform Medical Institutions of New R&D Cost Disclosure Plan in April
February 20, 2015
- AJMC Announces Guidelines for Investigator-Led Clinical Trials
February 20, 2015
- PhRMA Sets to Make Direct Plea to Finance Minister to Drop Annual Price Cut Plan
February 6, 2015
- Number of Contract Sales Reps Increased to 4,148 as of Oct. 2014: CSO Association
February 4, 2015
- JPWA President Reiterates Opposition to Annual NHI Price Revisions
February 2, 2015
- IMI, WADA Sign MOU to Prevent Use of Experimental Drugs for Doping
January 30, 2015
- July-Sept. Generic Share Reaches 51.3% under New Formula: JGA
January 30, 2015
- JPMA Draft Guidelines Urge Companies to Separate Ad Reviewing Bodies from Sales Units
January 27, 2015
- Chuikyo Members Divided on Usage of Savings from NHI Price Cuts
January 26, 2015
- 3-Price Bracket Rule for Generics Causing Various Distortions, Problems: JGA President
January 23, 2015
- Ihoken Proposes New Pricing Rule for Regenerative Medicines
January 22, 2015
- Some LDP Members Keen to Tackle Kampo NHI Price Problem
January 21, 2015
- JSMI to Announce in May a “Grand Design” for OTC Drug Industry
January 21, 2015
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…